EMERYVILLE, CA, September 09, 2002 — Biotique Systems, Inc. today announced that Fujisawa Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., and Metabolex, Inc. have joined the growing list of customers for the Biotique Local Integration System (BLIS) and extension products.

“We are delighted that our genome-based integration platform is gaining rapid recognition as a solution that meets the critical information management needs of both large and smaller biopharmaceutical companies,” said Stephen Sanders, chairman and chief executive officer for Biotique Systems, Inc. “We are also pleased to expand our network of customers to include two of Japan’s leading pharmaceutical companies, providing us with a strong entry into the Asia-Pacific market.”

“BLIS allows us to easily integrate any annotation that we generate, from expressed sequence tags to microarray probes, onto a genomic reference template,” said John Blume, Ph.D., vice president, strategic technologies for Metabolex, Inc. “As a result, we can securely visualize and analyze the information and begin to ask more intelligent and global questions of our data.”

Fujisawa Pharmaceutical Co., Ltd., headquartered in Osaka Japan, is a research driven pharmaceutical company with global operations. The company has net sales of more than $2 billion and a work force of more than 8,000.

Ono Pharmaceutical Co., Ltd. is an R&D-oriented, international pharmaceutical company with an emphasis on applying genomics to creating innovative medicines in the areas of prostaglandins, enzyme inhibitors, neuroscience and cellular signaling.

Metabolex, Inc., based in Hayward, California, is a privately held company founded to discover and develop therapeutics for diabetes. The company’s lead product, MBX-102, is a novel insulin sensitizer currently in Phase 1 clinical trials.

Biotique Systems, Inc. is a privately held company based in Emeryville, California founded in 2001 to solve critical issues in the life sciences. The company’s core product, BLIS, is a data integration, analysis and visualization platform that enables pharmaceutical and biotechnology companies to expedite target discovery and refinement using the human genome as a reference template. Biotique’s customers, which also include Bristol-Myers Squibb Company and Berlex Biosciences, Inc., are using BLIS to integrate disparate data for functional and comparative genomics, pharamcogenomics and other drug discovery research.